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Abstract 
Introduction: Sternal wound infection caused by Mycobacterium chelonae, a member of rapidly 
growing non-tuberculous mycobacteria, is rare and may present without signs and symptoms of 
systemic infection.   
Methods: We present a patient who had a Mycobacterium chelonae infection of the sternum 
following excision of a left atrial myxoma and conducted a review of the literature from 1976 to 
2013. 
Results: 70 cases of NTM sternal wound infection after cardiac surgery was identified, including 
6 outbreaks and 10 sporadic cases including the present case.  34 cases were isolated coronary 
artery bypass grafting surgery (CABG), 16 cases were isolated valve replacement and 2 cases 
were valve replacement with CABG.  The age range of the patients was between 6 and 78 years.  
The average time from the surgery was 49 ± 58 days which was longer than usual bacterial 
mediastinitis.  The overall mortality rate was 29%.   
Conclusion: NTM sternal wound infection is rare but may be fatal if not properly treated.  The 
toxic signs are often subtle and it will take longer to isolate compared to typical bacterial 
mediastinitis.  Early recognition, the use of appropriate antibiotics based on susceptibility tests 
and aggressive surgical debridement is required for full recovery.  (Word count of abstract: 
197) 
 
Key words: cardiac surgery, mediastinitis, mycobacterium, surgical site infection, acid fast 
bacilli  
 3 
Introduction 
Sternal wound infection has remained one of the most devastating complications of 
cardiac surgery with its incidence of 1-3%.1  The most common organisms are Staphylococci 
group and gram-negative bacilli.1  Therefore, standard prophylactic antibiotics are 
cephalosporins.2, 3  However, most non-tuberculous mycobacteria (NTM) are not sensitive to 
cephalosporins.4  We report a case of Mycobacterium chelonae infection of the sternum 
following excision of a left atrial myxoma in a 60-year-old man.  This case report illustrates the 
unique clinical presentation and the treatment for NTM sternal wound infection and would alert 
clinicians that NTM may be a cause of culture negative sternal wound infection. 
Case Report 
 A 60-year-old male with a past medical history of hypertension, hyperlipidemia and 
multiple episodes of right lower lobe pneumonia secondary to chronic aspiration was found to 
have a left atrial myxoma (4 x 2.5cm).  He underwent excision of the myxoma, which was 
complicated by postoperative bleeding and tamponade requiring re-exploration on postoperative 
day 0.  Otherwise, he had an uneventful hospital course and he was discharged to a 
rehabilitation facility on postoperative day 7.  Three months later, on a scheduled office visit, 
there was serosanguinous drainage from the sternal incision.  He denied pain, fever, chill, 
malaise or fatigue.  He was admitted to the hospital with a diagnosis of sternal wound infection.  
He was afebrile.  Physical examination showed mild serosanguinous drainage from the 
mid-sternal incision without erythema or tenderness.  Laboratory data showed white blood cell 
count (WBC) 7.6 B/L and procalcitonin 0.11 ng/ml.  Chest CT (Figure 1) showed a sub-sternal 
fluid collection with sternal dehiscence.  He was scheduled for a wound exploration and 
drainage in the operating room.  Antibiotics were not started until the operative exploration due 
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to his stable condition.  His sternal incision was opened, all the wires were removed, and the 
wound was closed with a vacuum assisted closing device.  The gram stain and acid-fast stain of 
the drainage and tissue obtained in the operating room showed no organisms.  The culture 
initially showed very light growth of coagulase negative staphylococcus and propionibacterium 
acnes; thus, vancomycin was started.  However, 5 days later, the culture turned positive for 
acid-fast organism.  Antibiotic regimens were modified to tobramycin, imipenem, moxifloxacin 
and clarithromycin, in addition to vancomycin.  He underwent a total sternectomy on 
postoperative day 6 and his chest was closed on postoperative day 12 with a pectoralis major 
muscle flaps.  The specimen was sent to FOCUS Diagnostics (Cypress, CA) for further 
speciation and susceptibility testing, and the organism was later identified as Mycobacterium 
chelonae.  The antibiotics were changed to tigecycline and clarithromycin based on the 
sensitivity.  Tigecycline was continued for 2 weeks.  He was discharged on postoperative day 
32 on oral clarithromycin, which was continued for 6 months.  He is currently being followed as 
an outpatient without relapse for 1 year. 
Discussion 
Bacteriology:  Mycobacterium chelonae is one of the species of rapidly growing NTM (RGM).  
The most common strains among RGM are Mycobacterium fortuitum, Mycobacterium abscessus 
and Mycobacterium chelonae.5  NTM is ubiquitous in the environment and has been isolated 
from house dust, raw and pasteurized milk, fish, cattle, soil and various water related sources, 
including water in hospital tanks as well as scrub sinks in operating room.2, 6, 7  They have been 
isolated from sputum and saliva of healthy adult humans.7  Some NTM strains are resistant to 
the commonly used disinfectants such as organomercurials, chlorine, formaldehyde, and alkaline 
glutaraldehyde.8 
Lung infection, post-traumatic wound infection, post surgical wound infection, and 
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catheter related infection are the common clinical manifestations caused by NTM.9  NTM was 
also reported to be the pathogen of meningitis, peritonitis, salpingitis, prostatitis and 
epididymitis.7  In cardiac surgery, 25 Hancock porcine valves implanted at ten medical centers 
were contaminated by M. chelonei subspecies chelonei in 1976-77.10, 11  These valves were 
found to be contaminated during the harvesting process from pigs,12 and the organism was 
relatively resistance to 2% formaldehyde which was used for valve sterilization.10, 13, 14  Two of 
the 24 patients (1 patient received 2 valves) developed mycobacterium infection; mycobacterial 
pericarditis and aortic root abscess.10  Few cases of isolated native valve endocarditis caused by 
M. abscessus are reported as well.15-17 
To the best of our knowledge, a total of 70 cases of NTM sternal wound infection after 
cardiac surgery were reported, including 6 outbreaks in the 1970s -1980s and 10 sporadic cases 
including the present case (Table 1).  Interestingly, all of the NTMs that were isolated from 
sternal wound infections were RGM.  M. fortuitum was isolated in most cases, followed by M. 
abscessus, and M. peregrinum.  An isolated case of M.porcinum sternal wound infection was 
reported from Spain, and M. smegmatis was submitted to Tyler Mycobacteria / Nocardia 
laboratory from sternal wound infection that occurred in Texas and California.18 
In 1966, M. fortuitum was divided into three subgroups; biotypes A, B and C, based on 
the differences in acid production from carbohydrates.9, 19  In 1974, Pattyn renamed them as M. 
fortuitum biovariant fortuitum, M. fortuitum biovariant peregrinum, and an unnamed third 
biovariant.9, 20  In early 1990s, based on genomic DNA studies, M. fortuitum biovariant 
fortuitum and M. fortuitum biovariant peregrinum were upgraded to species status, M. fortuitum 
and M. peregrinum respectively.9, 21, 22  Therefore, “M. fortuitum” infections reported before 
1990s may have not accurately separated the subgroups of M. fortuitum.  For example, the 
organism isolated in the second outbreak in Colorado was initially reported as “M. fortuitum” but 
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was later identified as M. fortuitum biovariant fortuitum.23  
Another RGM, M. chelonei was isolated from the lungs of turtles in 1903 by 
Friedmann24, and the name was changed to the more correct Latin; M. chelonae in 1984.25  M. 
abscessus was identified by Moore and Frerichs in 1953 from a knee abscess.  In the past, M. 
abscesses and M. chelonei were believed to be the same organism because they had almost 
identical biochemical features.  In 1972, Kubica demonstrated that M. chelonei and M. 
abscesses were different and needed to be classified as subspecies.  These were renamed as M. 
chelonae subspecies chelonae and M. chelonae subspecies abscessus.26  Genomic DNA studies 
showed that the two subspecies were different species, and once again, they were renamed as M. 
chelonae and M. abscessus in early 1990s.21, 22  Like in the case of M. fortuitum, little effort was 
made to differentiate the two species in the reports before 1990.9  The organism that was 
isolated in the first outbreak in North Carolina was initially reported to be “M. chelonei” but was 
later identified as M. chelonae subspecies abscessus.27  To the best of our knowledge, other than 
our report, sternal wound infections caused by M. chelonae (chelonei) have been only reported 
once, by Yew in 198828, when M. chelonei and M. abscessus might have not been differentiated. 
In most of the reported outbreaks of RGM sternal infection, the source-identification 
failed despite extensive workup.  In 1976, Robicsek reported an outbreak of RGM sternal 
infections that occurred in 19 of 80 patients who underwent cardiac surgery.29  He cultured 
materials used in the operating room such as bone wax, gauze, povidone-iodine, needle and wire, 
surgeon’s hair, nose, throat and hands, but was unsuccessful.  In another outbreak, Kuritsky 
reported that the water for cooling the cardioplegia solution in the operating room was considered 
to be a source of contamination by M. chelonae.30  From an epidemiological point of view, the 
fact that the reported outbreaks were caused by different strains, some outbreaks had more than 
one strain, the outbreaks occurred in areas of high endemicity of all forms of NTM infection, 
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suggests that the outbreaks of NTM infection could be more related to the local environmental 
source, rather than a contaminated surgical material.31 
Characteristics of NTM Sternal infection: Among the 70 cases of NTM sternal 
infections, 34 cases were isolated coronary artery bypass grafting surgery (CABG), 16 cases were 
isolated valve replacement and 2 cases were valve replacement with CABG.  The age range of 
the patients was between 6 and 78 years.  The patients were not necessarily 
immune-compromised; however, prolonged surgical exposure, the use of cardiopulmonary 
bypass, prosthetic material, intravenous and intra-arterial catheters for monitoring and infusion 
may increase the risk of nosocomial infections.32  Almost all patients had an uneventful 
postoperative course and most of the patients were initially discharged from hospital in a 
reasonable time period with stable condition.  
Sternal wound infections caused by RGM have unique manifestations compared to 
typical bacterial infections.  One of the interesting features of RGM sternal wound infection is 
the delayed onset, as in our case.  Although they are categorized as “rapidly growing” 
mycobacterium, the growth is slow compared to typical sternal infection organisms, such as 
Staphylococcus or gram negative bacilli.  Chow reported a case whose first symptom started 11 
months after the surgery.33  The average time from the surgery based on the available data was 
49 ± 58 days.  Whereas, typical bacterial sternal mediastinitis is reported to occur between 4 and 
30 days, mostly within the first 2 weeks.34  The patients with RGM sternal infection do not 
appear to be septic in most cases.29  High fever with elevated WBC is rare in RGM sternal 
infection, in contrast to typical bacterial mediastinitis which the patients frequently present with 
fever, elevated WBC count, and a septic picture.35, 36  Procalcitonin, a biomarker that increases 
in bacterial infection37, was only slightly elevated in our case.  Sternal drainage is the most 
common presentation of RGM sternal infection, and in most cases, the drainage was odorless and 
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watery rather than purulent.27  Presence of satellite abscesses are also characteristic.2  The 
initial aerobic and anaerobic cultures are usually negative, or it may grow normal flora of the skin, 
such as staphylococcus epidermidis or corynebacterium species.  RGM grows on blood or 
MacConckey’s agar but may take up to 7 days to culture.2  The delay of the isolation may cause 
delay in treatment, since the drug sensitivity is different from typical pathogen of sternal wound 
infection.7 
Antibiotics therapy: RGM is usually resistant to the first-line antituberculous drugs such as 
isoniazid, rifampin, and pyrazinamide.5, 38  In the reported outbreaks, antibiotics were selected 
based on sensitivity tests.27, 30  Hoffmann reported the use of kanamycin for 7-10 days, followed 
by erythromycin and rifampin.  Kuritsky reported the use of amikacin and cefoxitin.  Yew 
reported the efficacy of oral single daily dose oxacillin therapy.28  Clarithromycin is currently 
the drug of choice for M. chelonae and M. abscessus, because of the excellent tissue penetration, 
susceptibility and few side effects.35  Combination therapy is recommended to minimize the 
development of drug resistance.35, 39  Recently, linezolid, tigecycline, telithromycin, gatifloxacin 
are reported to be effective against RGM.8, 40  Approximately 50% of M. abscessus, 96% of M. 
fortuitum are susceptible to linezolid.8  At least 4 to 6 months of antibiotic treatment based on 
susceptibility test is recommended.8  In our case, clarithromycin was continued for 6 months. 
For sternal infection caused by M. chelonae, one of the injectable agents such as 
imipenem, tobramycin was recommended in combination with clarithromycin for at least the first 
2 weeks.9  Tobramycin is preferred to amikacin because of its greater in-vitro activity against M. 
chelonae.9  Oral agents such as minocycline and doxycycline are effective against only 20% of 
M. chelonae.9  Cefoxitin which is used for M. abscessus is uniformly resistant for M. chelonae.8   
For sternal infections caused by M. abscessus, amikacin plus cefoxitin or imipenem is 
used for the first 2 to 6 weeks in combination with clarithromycin, until clinical improvement is 
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evident.8, 9  M. abscessus is usually resistant against tobramycin.4  For the majority of M. 
abscessus and M. chelonae isolates, imipenem is the preferred carbapenem over meropenem and 
ertapenem.8 
Antibiotic therapy against M. fortuitum is much easier than M. abscessus or M. chelonae, 
since M. fortuitum is less drug resistant.  Amikacin, cefoxitin, imipenem, sulfamethoxazole, and 
fluoroquinolones are recommended.9  Amikacin combined with beta-lactam (cefoxitin or 
imipenem) or a quinolone is used for initial therapy against serious infection.  Yew reported the 
use of ofloxacin as a monotherapy41, but the development of mutational resistance resulted in 
treatment failure and relapse.9  Therefore, if a quinolone is used, an additional antimicrobial 
agent should be used.  80% of M. fortuitum are susceptible to clarithromycin, but recent studies 
have shown that all isolates of M. fortuitum contain an erythromycin methylase gene erm, which 
may induce macrolide resistance.8 
Surgical treatment: Surgical debridement in conjunction with appropriate antibiotic therapy 
is mandatory for complete recovery.  Among the 70 reported cases, almost all cases underwent 
extensive drainage and debridement.  All wires should be removed.  If the combination of 
surgical debridement and appropriate antibiotics fails to eliminate the infection, more aggressive 
approach such as sternectomy combined with a pectoralis flap or omental flap will be required. 
Outcomes: The outcome of the RGM sternal infection is not benign: 14 out of 49 cases died 
giving the overall mortality rate of 29%, although 21 cases did not report the outcome.  Of the 
14 deaths, 6 cases (75%, 6/8) had valve replacement surgery, 5 cases (19%, 5/26) had CABG, 
p=0.003.  The common cause of mortality was prolonged sepsis, prosthetic valve endocarditis, 
and stroke.  Robicsek reported that fatal hemorrhage from the aortotomy suture line and 
cannulation site, sepsis, prosthetic valve endocarditis resulting in stroke were the cause of 4 
deaths in an outbreak in North Carolina.29  Narasimhan reported a case that developed 
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mediastinitis 5 weeks after aortic valve replacement.  In that report, mediastinitis caused sepsis, 
and subsequently infected the prosthetic valve.  Emboli from the vegetation resulted in stroke 
and death.7  Chow reported a case of M. fortuitum superficial sternal wound infection that 
occurred 2 months after aortic and mitral valve replacement.  The sternal wound was healed 
completely after 4 weeks of ofloxacin treatment; however, the patient was readmitted for 
RGM-aortic root abscess 11 months later from the initial procedure and resulted in mortality.33   
In valve replacement surgery, prosthetic valves may be a nidus of RGM infection and would 
result in prolonged sepsis and endocarditis.  The additional suture lines would be susceptible to 
mediastinal infection, which will eventually lead to uncontrollable bleeding, causing a high 
mortality rate in valve replacement surgery, compared to CABG.27  If infection of RGM 
occurred after valve surgery and if the valve was infected, valve replacement with homograft 
should be considered. 
Conclusion: It is possible that many reported cases of culture negative sternal wound 
infection may be due to mycobacterial infections, especially if the patient had a delayed onset and 
failed to response to standard antibiotic therapy.  The diagnosis may be difficult, because the 
toxic signs are often subtle and it will take longer to isolate compared to typical bacteria.  Delay 
of specific treatment may result in dismal outcomes.  Early recognition, the use of appropriate 
antibiotics based on susceptibility tests and aggressive surgical debridement is required for full 
recovery. 
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Legends of figures 
Figure 1:  CT scan showed substernal fluid collection with sternal dehiscence. 
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Table 1:  Characteristics of the sternal infection caused by rapidly growing non-tuberculosis mycobacteria. 
Reference Year 
No. of 
cases  
(sex) 
Age 
range 
(median) 
Place Organism 
Duration 
after 
surgery 
(median) 
Fever 
Quality of 
drainage 
WBC 
(median) 
Long-term 
antibiotics 
Outcome 
Robicsek 1976 
19 
(15 male 
and 
4 female) 
42-66 
(57) 
North 
Carolina, 
USA 
M. chelonei 
subspecies 
abscessus 
6-40  
(14) days 
low grade 
no odor, 
more 
watery 
than 
purulent 
6.9-29.6 
(10.3) 
erythromycin and 
rifampin 
5 deaths 
Hoffman 1976 
5 
(3 male 
and 2 
female) 
30-70 
(54.5) 
Colorado, 
USA 
M. fortuitum 
6-44  
(25) days 
NA 
thick, 
whitish, 
cheesy, 
brown, or 
purulent 
7.0-18.5 
(9.2) 
rifampin, 
ethambutol, and 
isoniazid (4) 
 
ethionamide 
ethambutol, and 
isoniazid (1) 
all healed 
Jauregui 1977 
1 
(male) 
55 
Michigan, 
USA 
M. chelonei 
subspecies 
abscessus 
61 days 38°C 
yellowish, 
white 
9.4 
erythromycin and 
vancomycin 
death 
(bleeding 
from 
anastomo
sis) 
Szabo 1977 
6 
(sex 
unknown) 
NA Hungary 
M. chelonei 
subspecies 
abscessus 
11-45 
days 
fever (5) 
no fever (1) 
serous, 
containing 
yellowish 
fragment, 
odorless 
normal NA 3 deaths 
Narasimhan 1978 
1 
(male) 
57 
Canada 
(Ontario) 
M. fortuitum 5 weeks 38.5°C NA 4.8 
ethinamide, 
isoniazid, and 
rifampin 
1 death 
Preheim 
(reference 
Brown-Ell
iott 2002) 
1981 
5 
(sex 
unknown) 
NA 
Nebraska, 
USA 
M. fortuitum NA NA NA NA NA 1 death 
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Kuritsky 1981 
4 
(all male) 
49-76 
(62.5) 
Texas, 
USA 
M. chelonei 
subspecies 
abscessus,                      
M. fortuitum 
biovariant 
fortuitum 
21-92  
(26) days 
fever (2),  
no fever (2) 
NA NA 
amikacin and 
cefoxitin (2) 
 
amikacin, cefoxitin 
and doxycycline (1) 
1 death,  
3 healed 
Sethi 1982 1 (male) 61 
North 
Carolina, 
USA 
M. fortuitum 30 days 37.8°C 
serous, 
odorless 
4.4 
doxycycline, 
sulphamethoxazole, 
and ethionamide 
1 healed 
Kuhn 1983 
1 
(male) 
56 Indiana M. fortuitum 28 days low grade 
brown 
purulent 
 
ciprofloxacin, 
erythromycin, and 
amikacin  
1 death 
Yew 
1987 
- 
1989 
21 
(13 male 
and 8 
female) 
28-70 
(58) 
Hong Kong 
M. fortuitum 
biovariant 
fortuitum (7) 
M. fortuitum 
biovariant 
peregrinum (12) 
M. fortuitum third 
biovariant complex 
(2) 
0-2 
months 
NA NA NA NA NA 
Chow 1988 
1 
(female) 
45 Hong Kong M. fortuitum 11months NA NA NA oxacillin 1 death 
Samuels 1996 
1 
(female) 
49 PA, USA M. fortuitum 35 days low grade watery NA 
ciprofloxacin, 
sulfamethoxazole, 
and clarithromycin  
1 healed 
Syed 1997 
1 
(male) 
6 
Saudi 
Arabia 
M. fortuitum 19 days 38.5°C 
yellowish, 
odorless, 
thick pus 
 
amikacin, 
sulfamethoxazole 
and trimethoprim 
1 healed 
Idigoras 2003 
1 
(male) 
78 Spain M. porcinum 6 months NA pus NA ciprofloxacin 1 healed 
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Sarma 2010 
1 
(male) 
75 India M. abscessus 1 month No 
serosangui
nous 
10.4 
azithromycin, 
amikacin, and 
ciprofloxacin  
1 healed 
Unai 2013 
1 
(male) 
60 PA USA M. chelonae 3 months No 
serosangui
nous 
7.6 
tigecycline, and 
clarithromycin 
1 healed 
 
NA: not available; WBC: white blood cell count (B/L). 
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